• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sierra Oncology, Inc. - Common Stock (NQ:SRRA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sierra Oncology, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
June 17, 2022
From Sierra Oncology
Via Business Wire
News headline image
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 26, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
May 12, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Reports First Quarter 2022 Results
May 06, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From Sierra Oncology
Via Business Wire
News headline image
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
May 02, 2022
From Kuznicki Law PLLC
Via Business Wire
News headline image
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
April 25, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
News headline image
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
April 13, 2022
From Halper Sadeh LLP
Via Business Wire
News headline image
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
April 13, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 03, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology to Participate in Guggenheim Oncology Conference
February 03, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
January 31, 2022
From Sierra Oncology
Via Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
January 27, 2022
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
News headline image
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
January 27, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
January 26, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Proposed Public Offering of Common Stock
January 25, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
January 25, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
January 25, 2022
From Sierra Oncology
Via Business Wire
News headline image
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
January 19, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
January 18, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 07, 2022
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology to Present at HC Wainwright BioConnect Conference
January 05, 2022
From Sierra Oncology, Inc.
Via Business Wire
News headline image
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients
December 13, 2021
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis
December 06, 2021
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2021
From Sierra Oncology
Via Business Wire
News headline image
Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
November 12, 2021
From Sierra Oncology
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap